Is the current dosing of acamprosate 999 mg twice daily and naltrexone 50 mg daily appropriate, and how should it be adjusted?

Acamprosate Dosing Error - Immediate Correction Required

The current acamprosate dose of 999 mg twice daily is incorrect and should be changed to 666 mg three times daily (total 1998 mg/day), while the naltrexone 50 mg daily is appropriately dosed. 1, 2

Correct Dosing Regimen

Acamprosate

• Standard dose: 666 mg (two 333 mg tablets) three times daily for patients ≥60 kg
• Total daily dose: 1998 mg/day
• For patients <60 kg: reduce to 1332 mg/day (two 333 mg tablets twice daily, then one 333 mg tablet for the third dose)
• The current regimen of 999 mg BID provides only 1998 mg/day but with incorrect timing that may compromise efficacy 1

Naltrexone

• 50 mg once daily is correct 2
• This is the FDA-approved standard dose for alcohol use disorder treatment

Why This Matters

Acamprosate requires three-times-daily dosing because:

• Terminal elimination half-life is 20-33 hours with the enteric-coated formulation 1
• Steady-state is reached in 5-7 days with TID dosing 1, 3
• The medication exhibits flip-flop kinetics, making consistent dosing intervals important for maintaining therapeutic plasma concentrations (370-650 mcg/L at steady state) 3

Safety Profile of This Combination

This combination is safe and well-tolerated based on multiple pharmacokinetic studies 4, 5:

• No contraindication to co-administration exists
• Naltrexone increases acamprosate absorption by 25-33% (likely by prolonging gastric emptying), which is not clinically harmful 4, 5
• Acamprosate does not affect naltrexone or its metabolite (6-beta-naltrexol) pharmacokinetics 4
• No negative cognitive or safety interactions have been documented 4

Liver Disease Considerations

Both medications are appropriate for patients with alcohol-related liver disease, with important caveats:

• Acamprosate: Safe in liver disease as it undergoes no hepatic metabolism and is renally excreted 6, 7, 1. The presence of liver disease does not change dosing (G2+ recommendation) 7

• Naltrexone: Technically contraindicated in hepatic insufficiency per FDA labeling 2, but recent guidelines note this "absolute contraindication is not supported by solid data" and recommend case-by-case assessment 7. However, hepatotoxicity concerns exist with naltrexone 6

Critical Renal Function Check

Before continuing acamprosate, verify renal function immediately:

• If creatinine clearance 30-50 mL/min: reduce to 333 mg TID 1
• If creatinine clearance ≤30 mL/min: acamprosate is contraindicated 1
• Acamprosate concentrations increase 2-fold with moderate and 4-fold with severe renal impairment 1

Implementation Algorithm

1. Assess renal function (creatinine clearance)
2. If CrCl >50 mL/min: Change to acamprosate 666 mg TID + naltrexone 50 mg daily
3. If CrCl 30-50 mL/min: Change to acamprosate 333 mg TID + naltrexone 50 mg daily
4. If CrCl <30 mL/min: Discontinue acamprosate; continue naltrexone 50 mg daily alone (if liver function permits)
5. If severe liver disease present: Consider discontinuing naltrexone and using acamprosate alone (if renal function adequate) or switching to baclofen 6, 7

Evidence for Combination Therapy

While both medications are FDA-approved for alcohol use disorder 6, 7, evidence for combination therapy is limited but supportive:

• Acamprosate is more effective for maintaining abstinence (NNT=12) 8, 9
• Naltrexone is more effective for reducing heavy drinking (NNT=12 for preventing heavy drinking) 8, 9
• Combination therapy may be considered when monotherapy fails 10, though large trials (COMBINE study) showed mixed results
• The combination is safe with no pharmacological contraindications 4, 5

Food effect: Acamprosate absorption decreases with food (42% reduction in Cmax), but this is not clinically significant and no timing adjustment relative to meals is required 1.